Search Results - "John F. Paolini"

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis by Klein, Allan L, Imazio, Massimo, Cremer, Paul, Brucato, Antonio, Abbate, Antonio, Fang, Fang, Insalaco, Antonella, LeWinter, Martin, Lewis, Basil S, Lin, David, Luis, Sushil A, Nicholls, Stephen J, Pano, Arian, Wheeler, Alistair, Paolini, John F

“…Patients with recurrent pericarditis were treated with the interleukin-1 trap rilonacept. Those who had a response were randomly assigned to receive continued…”
Get full text

Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta by Hashimoto, Takashi, Nattkemper, Leigh A., Kim, Hei Sung, Kursewicz, Christina D., Fowler, Emilie, Shah, Serena M., Nanda, Sonali, Fayne, Rachel A., Paolini, John F., Romanelli, Paolo, Yosipovitch, Gil

“…Prurigo nodularis (PN) is a chronic skin dermatosis with hyperkeratotic and intensely pruritic nodules. Managing PN‐associated itch is difficult because its…”
Get full text

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF by Hankey, Graeme J, Prof, Patel, Manesh R, MD, Stevens, Susanna R, MSc, Becker, Richard C, MD, Breithardt, Günter, MD, Carolei, Antonio, Prof, Diener, Hans-Christoph, MD, Donnan, Geoffrey A, MD, Halperin, Jonathan L, Prof, Mahaffey, Kenneth W, MD, Mas, Jean-Louis, MD, Massaro, Ayrton, MD, Norrving, Bo, MD, Nessel, Christopher C, MD, Paolini, John F, MD, Roine, Risto O, MD, Singer, Daniel E, Prof, Wong, Lawrence, MD, Califf, Robert M, Prof, Fox, Keith AA, Prof, Hacke, Werner, MD

“…Summary Background In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial…”
Get full text

Factors Associated With Major Bleeding Events by Goodman, Shaun G., MD, MSc, Wojdyla, Daniel M., MS, Piccini, Jonathan P., MD, White, Harvey D., MB, ChB, DSc, Paolini, John F., MD, PhD, Nessel, Christopher C., MD, Berkowitz, Scott D., MD, Mahaffey, Kenneth W., MD, Patel, Manesh R., MD, Sherwood, Matthew W., MD, Becker, Richard C., MD, Halperin, Jonathan L., MD, Hacke, Werner, MD, Singer, Daniel E., MD, Hankey, Graeme J., MD, Breithardt, Gunter, MD, Fox, Keith A.A., MB, ChB, Califf, Robert M., MD

“…Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with…”
Get full text

CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice by Tardy, Claudine, Goffinet, Marine, Boubekeur, Nadia, Ackermann, Rose, Sy, Gavin, Bluteau, Alice, Cholez, Guy, Keyserling, Constance, Lalwani, Narendra, Paolini, John F, Dasseux, Jean-Louis, Barbaras, Ronald, Baron, Rudi

“…Abstract Objective CER-001 is a novel engineered HDL-mimetic comprised of recombinant human apoA-I and phospholipids that was designed to mimic the beneficial…”
Get full text

Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation by Tanigawa, Takahiko, Kaneko, Masato, Hashizume, Kensei, Kajikawa, Mariko, Ueda, Hitoshi, Tajiri, Masahiro, Paolini, John F., Mueck, Wolfgang

“…The global ROCKET AF phase III trial evaluated rivaroxaban 20 mg once daily (o.d.) for stroke prevention in atrial fibrillation (AF). Based on rivaroxaban…”
Get full text

Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept by Imazio, Massimo, Klein, Allan L, Brucato, Antonio, Abbate, Antonio, Arad, Michael, Cremer, Paul C, Insalaco, Antonella, LeWinter, Martin M, Lewis, Basil S, Lin, David, Luis, Sushil A, Nicholls, Stephen J, Sutej, Paul, Wasserstrum, Yishay, Clair, JoAnn, Agarwal, Indra, Wang, Sheldon, Paolini, John F

“…Rilonacept, a once-weekly interleukin-1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of…”
Get full text

Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA[S] by Kootte, Ruud S., Smits, Loek P., van der Valk, Fleur M., Dasseux, Jean-Louis, Keyserling, Constance H., Barbaras, Ronald, Paolini, John F., Santos, Raul D., van Dijk, Theo H., Dallinga-van Thie, Geesje M., Nederveen, Aart J., Mulder, WillemJ.M., Hovingh, G.Kees, Kastelein, JohnJ.P., Groen, Albert K., Stroes, ErikS

“…Reverse cholesterol transport (RCT) contributes to the anti-atherogenic effects of HDL. Patients with the orphan disease, familial hypoalphalipoproteinemia…”
Get full text

Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716 by Richards, Carl D, Gandhi, Rohan, Botelho, Fernando, Ho, Lilian, Paolini, John F

“…To evaluate cellular response to oncostatin M (OSM) in comparison to interleukin (IL)-31, we analyzed monocyte chemoattractant protein 1 (MCP-1) as a readout…”
Get full text

HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation by Tardy, Claudine, Goffinet, Marine, Boubekeur, Nadia, Cholez, Guy, Ackermann, Rose, Sy, Gavin, Keyserling, Constance, Lalwani, Narendra, Paolini, John F, Dasseux, Jean-Louis, Barbaras, Ronald, Baron, Rudi

“…CER-001 is a novel engineered HDL-mimetic comprised of recombinant human apoA-I and charged phospholipids that was designed to mimic the beneficial properties…”
Get full text

Reply to Albulushi et al.—Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From RHAPSODY Long-term Extension by Brucato, Antonio, Klein, Allan L., Imazio, Massimo, Paolini, John F.

Get full text

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression by Lauring, Brett, Taggart, Andrew K P, Tata, James R, Dunbar, Richard, Caro, Luzelena, Cheng, Kang, Chin, Jayne, Colletti, Steven L, Cote, Josee, Khalilieh, Sauzanne, Liu, Jiajun, Luo, Wen-Lin, Maclean, Alexandra A, Peterson, Laurence B, Polis, Adam B, Sirah, Waheeda, Wu, Tsuei-Ju, Liu, Xuan, Jin, Lan, Wu, Kenneth, Boatman, P Douglas, Semple, Graeme, Behan, Dominic P, Connolly, Daniel T, Lai, Eseng, Wagner, John A, Wright, Samuel D, Cuffie, Cynthia, Mitchel, Yale B, Rader, Daniel J, Paolini, John F, Waters, M Gerard, Plump, Andrew

“…Nicotinic acid (niacin) induces beneficial changes in serum lipoproteins and has been associated with beneficial cardiovascular effects. Niacin reduces…”
Get more information

Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept by Lin, David, Klein, Allan, Cella, David, Beutler, Anna, Fang, Fang, Magestro, Matt, Cremer, Paul, LeWinter, Martin M, Luis, Sushil Allen, Abbate, Antonio, Ertel, Andrew, Litcher-Kelly, Leighann, Klooster, Brittany, Paolini, John F

“…Impact of recurrent pericarditis (RP) on patient health-related quality of life (HRQoL) was evaluated through qualitative patient interviews and as an…”
Get full text

Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY by Brucato, Antonio, Lim‐Watson, Michelle Z., Klein, Allan, Imazio, Massimo, Cella, David, Cremer, Paul, LeWinter, Martin M., Luis, Sushil Allen, Lin, David, Lotan, Dor, Pancrazi, Massimo, Trotta, Lucia, Klooster, Brittany, Litcher‐Kelly, Leighann, Zou, Liangxing, Magestro, Matt, Wheeler, Alistair, Paolini, John F., Abbate, Antonio, Abo‐Auda, Wael, Akhtar, Asif, Arad, Michael, Atar, Shaul, Baibhav, Bipul, Bhalla, Karan, Brucato, Antonio, Collins, Sean, Colquhoun, David, Cremer, Paul, Cross, David, Dwivedi, Girish, Eisen, Alon, Freedberg, Nahum, Fuchs, Shmuel, Gaddam, Eliyazar, Gattorno, Marco, Gelfand, Eli, Grena, Paul, Halabi, Majdi, Harris, David, Imazio, Massimo, Insalaco, Antonella, Karim, Amin, Klein, Allan, Knowlton, Kirk, Kontzias, Apostolos, Kornberg, Robert, Latif, Faisal, Leibowitz, David, LeWinter, Martin, Lin, David, Lotan, Dor

“…Background Recurrent pericarditis is characterized by painful flares and inflammation, which negatively impact health‐related quality of life. RHAPSODY…”
Get full text

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia by Paolini, John F., MD, PhD, Mitchel, Yale B., MD, Reyes, Robert, BA, Kher, Uma, PhD, Lai, Eseng, MD, PhD, Watson, Douglas J., PhD, MSPH, Norquist, Josephine M., MS, Meehan, Alan G., PhD, Bays, Harold E., MD, Davidson, Michael, MD, Ballantyne, Christie M., MD

“…Niacin (nicotinic acid) is not optimally used mainly because of flushing, a process mediated primarily by prostaglandin D2 , which leads to poor patient…”
Get full text

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease by Maccubbin, Darbie, PhD, Koren, Michael J., MD, Davidson, Michael, MD, Gavish, Dov, MD, Pasternak, Richard C., MD, Macdonell, Geraldine, MHA, Mallick, Madhuja, PhD, Sisk, Christine McCrary, BS, Paolini, John F., MD, PhD, Mitchel, Yale, MD

“…Niacin has beneficial effects on a patient's lipid and lipoprotein profiles and cardiovascular risk, particularly at doses >2 g/day, but is underused due to…”
Get full text

Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: A post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients by Bays, Harold E., MD, Maccubbin, Darbie, PhD, Meehan, Alan G., PhD, Kuznetsova, Olga, PhD, Mitchel, Yale B., MD, Paolini, John F., MD

“…Abstract Background: Dyslipidemia and high blood pressure are both major cardiovascular disease risk factors. Niacin is an effective lipid-altering agent that…”
Get full text

Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody by Muralidharan, Sujatha, Njenga, Moses, Garron, Tracy, Bondensgaard, Kent, Paolini, John F

“…The CD40/CD40L pathway plays a major role in multiple inflammatory processes involving different immune and stromal cells. Abnormal activation of this pathway…”
Get full text

Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report by Mohiuddin, Muhammad M, Singh, Avneesh K, Scobie, Linda, Goerlich, Corbin E, Grazioli, Alison, Saharia, Kapil, Crossan, Claire, Burke, Allen, Drachenberg, Cinthia, Oguz, Cihan, Zhang, Tianshu, Lewis, Billeta, Hershfeld, Alena, Sentz, Faith, Tatarov, Ivan, Mudd, Sarah, Braileanu, Gheorghe, Rice, Kathryn, Paolini, John F, Bondensgaard, Kent, Vaught, Todd, Kuravi, Kasinath, Sorrells, Lori, Dandro, Amy, Ayares, David, Lau, Christine, Griffith, Bartley P

“…A genetically engineered pig cardiac xenotransplantation was done on Jan 7, 2022, in a non-ambulatory male patient, aged 57 years, with end-stage heart…”
Get full text

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial by Cid, Maria C, Unizony, Sebastian H, Blockmans, Daniel, Brouwer, Elisabeth, Dagna, Lorenzo, Dasgupta, Bhaskar, Hellmich, Bernhard, Molloy, Eamonn, Salvarani, Carlo, Trapnell, Bruce C, Warrington, Kenneth J, Wicks, Ian, Samant, Manoj, Zhou, Teresa, Pupim, Lara, Paolini, John F

“…Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF…”
Get more information